R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition

被引:3
|
作者
Sears, Thomas K. [1 ]
Woolard, Kevin D. [2 ]
机构
[1] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA
[2] UC Davis Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA USA
关键词
Mutant isocitrate dehydrogenase 1; 2 (IDH1; 2); Glioma; Bromodomain inhibition; Bromodomain and extraterminal (BET); JQ1; BRD4; PLURIPOTENCY; JQ1;
D O I
10.1007/s00432-022-04018-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Mutations in isocitrate dehydrogenase 1/2 (IDHmut) identify a subset of gliomas that exhibit epigenetic dysregulation via aberrant DNA methylation. These tumors are ultimately fatal and lack effective therapeutic strategies. Considering the epigenetic dysregulation of IDHmut gliomas, we hypothesized that epigenetic-targeting drugs may yield therapeutic benefits in gliomas bearing IDHmut. One set of targets includes the bromodomain and extraterminal (BET) family of transcriptional coactivators. Methods We used TCGA data from glioma patients to determine whether BET proteins affect patient survival differently based on IDH status. Follow-up experiments using a set of IDH wildtype/mutant glioma cultures, as well as an IDH wildtype glioblastoma cell line expressing exogenous R132H IDH1, focused on cell health assays to investigate whether IDHmut was associated with increased sensitivity to the BET inhibitor JQ1. Immunoblots were used to evaluate the molecular response to JQ1 in these cultures. Results We identified that high BRD4 expression associated with decreased survival only in IDHmut glioma patients. Cell viability analysis showed that IDHmut sensitized glioma cells to delayed cytotoxicity (10 days) in response to JQ1. Early effects of JQ1 (3 days) were primarily antiproliferative, with IDHmut glioma exhibiting a modest increase in sensitivity. Finally, exogenous R132H IDH1 expression in a resistant IDH wildtype cell line recapitulated the JQ1-mediated delayed cytotoxicity seen in our endogenous IDHmut glioma cells. Conclusion Overall, these data suggest that BRD4 enhances malignancy primarily in gliomas bearing IDHmut and is associated with greater sensitivity to BET inhibition. The finding that BET inhibition primarily exhibits delayed cytotoxicity may be overlooked in conventional short endpoint dose-response assays. Follow-up mechanistic and animal studies will help address the translational potential of these findings.
引用
收藏
页码:2275 / 2285
页数:11
相关论文
共 50 条
  • [21] IDH1R132H Mutant Glioma and Its Compensatory Mechanisms for Maintaining Telomeres
    Si-Xiang, Yan
    Yi-Fan, Li
    Yao, Li
    Yi-Xuan, Li
    Xiang-Xiu, Li
    Jin-Kai, Tong
    Shu-Ting, Jia
    Ju-Hua, Dan
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2024, 51 (11) : 2845 - 2852
  • [22] Nanomechanical Signatures in Glioma Cells Depend on CD44 Distribution in IDH1 Wild-Type but Not in IDH1R132H Mutant Early-Passage Cultures
    Shmelev, Mikhail E.
    Farniev, Vladislav M.
    Shved, Nikita A.
    Kumeiko, Vadim V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [23] Spontaneous In Vitro Senescence of Glioma Cells Confirmed by an Antibody Against IDH1R132H
    Stoczynsica-Fidelus, Ewelina
    Och, Waldemar
    Rieske, Piotr
    Bienkowski, Michal
    Banaszczyk, Mateusz
    Winiecka-Klimek, Marta
    Zieba, Jolanta
    Janik, Karolina
    Rosiak, Kamila
    Treda, Cezary
    Stawski, Robert
    Radomiak-Zaluska, Anna
    Piaskowski, Sylwester
    ANTICANCER RESEARCH, 2014, 34 (06) : 2859 - 2867
  • [24] R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes
    Shota Kawakami
    Kazuhiko Ochiai
    Daigo Azakami
    Yuiko Kato
    Masaki Michishita
    Masami Morimatsu
    Toshina Ishiguro-Oonuma
    Eri Onozawa
    Masami Watanabe
    Toshinori Omi
    Veterinary Research Communications, 2018, 42 : 49 - 56
  • [25] R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes
    Kawakami, Shota
    Ochiai, Kazuhiko
    Azakami, Daigo
    Kato, Yuiko
    Michishita, Masaki
    Morimatsu, Masami
    Ishiguro-Oonuma, Toshina
    Onozawa, Eri
    Watanabe, Masami
    Omi, Toshinori
    VETERINARY RESEARCH COMMUNICATIONS, 2018, 42 (01) : 49 - 56
  • [26] Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential
    Tiburcio, Patricia D. B.
    Gillespie, David L.
    Jensen, Randy L.
    Huang, L. Eric
    JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (03) : 427 - 437
  • [27] Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence
    Sabit, Hemragul
    Nakada, Mitsutoshi
    Furuta, Takuya
    Watanabe, Takuya
    Hayashi, Yutaka
    Sato, Hiroshi
    Kato, Yukinari
    Hamada, Jun-ichiro
    BRAIN TUMOR PATHOLOGY, 2014, 31 (04) : 242 - 246
  • [28] Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence
    Hemragul Sabit
    Mitsutoshi Nakada
    Takuya Furuta
    Takuya Watanabe
    Yutaka Hayashi
    Hiroshi Sato
    Yukinari Kato
    Jun-ichiro Hamada
    Brain Tumor Pathology, 2014, 31 : 242 - 246
  • [29] Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential
    Patricia D. B. Tiburcio
    David L. Gillespie
    Randy L. Jensen
    L. Eric Huang
    Journal of Neuro-Oncology, 2020, 146 : 427 - 437
  • [30] High EZH2 Protein Expression Is a Poor Prognostic Predictor in IDH1 R132H-Negative Gliomas
    Wong, Yin Ping
    Aziz, Roziasyazni Che Abdul
    Aizuddin, Azimatun Noor
    Saleh, Muhamad Fakhri Mohd
    Arshad, Roslina Mohd
    Tan, Geok Chin
    DIAGNOSTICS, 2022, 12 (10)